UPDATED: On the ropes, GlaxoSmithKline admits to another PhIII debacle

John Carroll GlaxoSmithKline, which recruited more than 16,000 patients in a monumental postapproval effort to distinguish Breo Ellipta by improving the mortality rates of high-risk ...

Novartis CEO: Payers not sold on performance pricing yet, but that’ll change

Tracy Staton Novartis CEO Joe Jimenez sees a couple of rays of hope for drug spending–and for the viability of higher-priced meds. Big Data, for one. And performance-based pricing ...

Celyad set to scale up China-focused R&D activities after linking with Medisun

Nick Paul Taylor Cell therapy specialist Celyad is set to add Hong Kong to the clinical trial program of its ischemic heart failure treatment, giving its newly recruited partner Medisun ...

Judge halts lawsuit blaming Purdue, Endo and others for epidemic of drug abuse

Eric Palmer It was attention-grabbing when California sued a handful of drugmakers, accusing them of lying about the safety of their high-powered painkillers and blaming them for an ...

Buzz: Ariad soars on reports that Baxalta has come calling about a buyout

John Carroll Shire has been quiet since making its unwelcomed $ 30 billion bid to acquire Baxalta public earlier this month. But Baxalta evidently isn't waiting for the next step ...

Eyeing first profits, Tillman Gerngross’s Avitide nabs one last VC round

John Carroll When serial biotech entrepreneur and Dartmouth scientist Tillman Gerngross co-founded Avitide in early 2013, he had some specific ideas on how to quickly capitalize on ...

Cancer docs try to rally public behind plan to fight drug prices

Eric Palmer Cancer doctors at the famed Mayo Clinic have been up in arms about escalating prices of cancer drugs. Now they have recruited a bunch of colleagues and are trying to rile ...

Eylea expected to keep delivering for Regeneron as Praluent starts to step up

Carly Helfand Eye blockbuster Eylea has been churning out serious revenue growth for Regeneron since it hit the market, and now the company is inching closer to approval for its much-watched ...

Ex-Pharmacyclics team raises $33.5M for checkpoint drug

John Carroll Ex-Pharmacyclics CEO Richard Miller is looking for a second act in biotech with his startup Corvus Pharmaceuticals. FierceBiotech News

HIV investigators at Harvard, J&J see promise in early-stage vaccine

John Carroll A team of collaborators drawn from Harvard, Johnson & Johnson and other groups published results from a preclinical animal study Thursday afternoon that underscores ...

Pharma to EU officials: We need ‘contingency’ supply plans in case of ‘Grexit’

Tracy Staton Drugmakers are raising an alarm about shortages in Greece as the possibility of a "Grexit" looms. That "worst-case scenario" could put supplies in peril, ...

Are CV studies worth it for diabetes meds? After Merck and Sanofi’s recent successes, some say no

Carly Helfand Some industry watchers are wondering whether those large, expensive trials–which aren't long enough to establish long-term outcomes–were worth it. FiercePharma ...
Page 4 of 98« First...23456...102030...Last »
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS